Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (≥60 years) with non-Hodgkin's lymphoma: Comparison with patients <60 years treated within the same protocol

Bone Marrow Transplantation

Volumn 26, Issue 7, 2000, Pages 737-741

  Jantunen, E ^a   Mahlamaki E ^a   Nousiainen, T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Elderly patients; High dose therapy; Lymphoma; Stem cell transplantation; Toxicity

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA LACTAM; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MESNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ELDERLY CARE; FEMALE; HOSPITALIZATION; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033764938     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702577     Document Type: Article

References (21)

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma
2. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
3. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front line chemotherapy: randomized Italian multicenter trial
4. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma
5. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH 87-2
6. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
7. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: Results from the European Group for Bone Marrow Transplantation
8. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant
9. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies
10. Non-Hodgkin's lymphoma in elderly patients
11. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma
12. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma
13. The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma
14. Reporting results of cancer treatment
15. Peripheral stem cell mobilization and engraftment in patients over age 60
16. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age
17. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61-65 years: A pilot study
18. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: An interim report
19. The modification of melphalan toxicity in tumor bearing mice by S-2(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721)
20. + counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
21. Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis-are there new strategies?